湖滨生物治疗

最新新闻

• Morgan Stanley Maintains Lakefront Biotherapeutics(LKFT.US) With Hold Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• RBC Capital Initiates Lakefront Biotherapeutics(LKFT.US) With Hold Rating, Announces Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/5/13
• Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR)
  TipRanks · 2026/8/10
• RBC Capital Upgrades Lakefront Biotherapeutics(LKFT.US) to Buy Rating, Raises Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• Morgan Stanley Upgrades Lakefront Biotherapeutics(LKFT.US) to Hold Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。